1 study found for:    NCT00901901
Show Display Options
Rank Status Study
1 Active, not recruiting
Has Results
Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006);   Drug: Sorafenib (Nexavar, BAY43-9006) + Erlotinib, Tarceva

Indicates status has not been verified in more than two years